Study Using PET/CT to Characterize the Effect of Reslizumab on Airway Inflammation

Study Title
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
Teva Identifier
C38072-AS-40105
ClinicalTrials.gov Identifier
NCT02937168
Study Status
Terminated
Trial Condition(s)
Asthma
Interventions
Drug: Reslizumab | Drug: Fludeoxyglucose F 18 (FDG) | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 50 Years
Trial Duration
May 8, 2017 - May 24, 2017
Phase
Phase 4

Study Type

Interventional